NAMD’s Recommendations on CMS’ Prescription Drugs Prior Authorization Interoperability Proposed Rule
This resource provides a high-level summary of NAMD’s comments on the 2026 CMS’ Interoperability Standards and Prior Authorization...
Letter ·
NAMD Comments on Medicare’s Proposed Coverage Determination for Alzheimer’s Drug
On February 9, 2022, NAMD submitted comments on Medicare’s proposed National Coverage Determination (NCD) of Coverage with Evidence Development (CED) for monoclonal antibody treatments for Alzheimer’s disease.
On February 9, 2022, NAMD submitted comments on Medicare’s proposed National Coverage Determination (NCD) of Coverage with Evidence Development (CED) for monoclonal antibody treatments for Alzheimer’s disease. In these comments, NAMD underscored that the proposed coverage determination may have significant financial impacts on state Medicaid programs, and that states must therefore retain the ability to set appropriate Medicaid utilization controls. NAMD also encouraged Congress to explore additional tools to help state Medicaid programs address future high-cost specialty drugs.
Related resources
NAMD Comments on the 2026 CMS’ Interoperability Standards and Prior Authorization for Drugs Proposed Rule
On June 15, 2026, NAMD formally commented on CMS’ Interoperability Standards and Prior Authorization for Drugs Proposed Rule.
A Q&A with Tennessee’s Medicaid Director Stephen Smith on Innovation and Thinking Outside the Box
Tennessee Medicaid Director Stephen Smith talks innovation, fiscal discipline, and what TennCare's unique shared-savings waiver has made possible—from...
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.